Tests elecoglipron against placebo in adults with chronic kidney disease
Tests elecoglipron versus placebo in adults with chronic kidney disease, alongside standard care.
Plain-language title generated from the registry record
Registry title: A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
Key facts
- Where
- Bordeaux, Clermont-Ferrand, Corbeil-Essonnes, Epagny Metz-tessy, Grenoble Cedex 9, La Rochelle, Laval, Le Kremlin-Bicetre, Le Puy-En-Velay, Lyon, Montpellier, Nantes, Orleans Cedex 2, Pierre-Bénite, Pontoise, Saint-Priest-en-Jarez, Toulouse Cedex 9, and Valenciennes, FranceSee the 18 sites
- Phase
- Phase 3
Where in France
- Centre hospitalier Universitaire de BordeauxBordeaux, FranceTaking people
- Chu Gabriel MontpiedClermont-Ferrand, FranceTaking people
- Centre Hospitalier Sud FrancilienCorbeil-Essonnes, FranceTaking people
- Centre Hospitalier Annecy GenevoisEpagny Metz-tessy, FranceTaking people
- Centre Hospitalier Universitaire Grenoble AlpesGrenoble Cedex 9, FranceTaking people
- Centre Hospitalier Groupe Hospitalier De La Rochelle Re AunisLa Rochelle, FranceTaking people
- Centre Hospitalier De LavalLaval, FranceTaking people
- Assistance Publique Hopitaux De ParisLe Kremlin-Bicetre, FranceTaking people
- Centre Hospitalier Du PuyLe Puy-En-Velay, FranceTaking people
- Centre Hospitalier Saint Joseph Saint LucLyon, FranceTaking people
- Centre Hospitalier Universitaire de MontpellierMontpellier, FranceTaking people
- Hospital Hotel DieuNantes, FranceTaking people
- Centre Hospitalier Universitaire D OrleansOrleans Cedex 2, FranceTaking people
- Hospices Civils de LyonPierre-Bénite, FranceTaking people
- Hôpital NOVOPontoise, FranceTaking people
- Centre Hospitalier Universitaire de Saint EtienneSaint-Priest-en-Jarez, FranceTaking people
- Centre Hospitalier Universitaire De ToulouseToulouse Cedex 9, FranceTaking people
- Centre Hospitalier de ValenciennesValenciennes, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07753993EU 2025-523994-41-00
- Record updated
- 9 September 2026
- Original description
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compared with placebo in participants with CKD with and without T2DM who are on background SGLT2i (dapagliflozin) as GDMT and other SoC treatments for CKD.Read full original descriptionShow less
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants With Chronic Kidney Disease (Elevate-CKD)
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compared with placebo in participants with CKD with and without T2DM who are on background SGLT2i (dapagliflozin) as GDMT and other SoC treatments for CKD.
Inclusion: Adults with confirmed CKD; UACR ≥30 mg/g and eGFR ≥20 mL/min/1.73 m² within specified ranges; On stable, patient maximum tolerated, labeled daily dose of ACEI or ARB for ≥4 weeks at least 28 days before screening.
Exclusion: Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema; Have had more than one episode of severe hypoglycemia within 180 days prior to screening, or hypoglycemia unawareness; Acute coronary syndrome, major cardiac procedure, stroke, or TIA within 3 months prior to screening; History of type 1 diabetes mellitus; Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying; History of acute or chronic pancreatitis; History/family history (first degree) of medullary thyroid cancer or MEN2; HbA1c ≥10% (86 mmol/mol) at screening; BMI <23 kg/m² at screening.